Chardan Capital analyst Matthew Barcus downgrades Oncorus (NASDAQ:ONCR) from Buy to Neutral.
What’s Going On With ResMed Stock Today
ResMed Inc (NYSE: RMD) posted Q3 profits of $247.8 million, with adjusted EPS of $1.68, up from $1.32 a year ago, beating the consensus of $1.59.
Revenues increased 29% to $1.12 billion, as continued growth reflects a ramp-up in production due to growing demand.
